Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (early primary spermatocytes) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 126 Parkinson's papers of 42,451 | 0.36 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 16488
Sealed predictions
- GML in dopamine neurons, braak+0.18 (p 0.646) → -0.27 (p 0.485)receipt 16494
Swarm cases
receipt 16494: GML in dopamine neurons, braak
- power
- full sample +0.10 (p 0.690, n 18), 95% CI -0.38 to +0.54. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.08 (p 0.767, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.10 (p 0.683, n 18). could be the mix.
- skeptic
- leave-one-out range -0.04 to +0.21, sign flips 1; without severely affected donors +0.10 (p 0.690, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for GML in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts